Advertisement

Topics

Moderate-to-Severe Plaque Psoriasis - Biotech, Pharma and Life Science Channel

04:03 EDT 22nd September 2017 | BioPortfolio

Psoriasis is a chronic, immune disease that affects the skin. It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis affects up to 1.8 million people in the UK,ix approximately 20 percent of whom have moderate-to-severe plaque psoriasis.Psoriasis can occur on any part of the body and is associated with other serious health conditions, such as diabetes and heart disease. The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells.

News Articles [135 Associated News Articles listed on BioPortfolio]

FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis

HORSHAM, Pa., July 21, 2011 /PRNewswire/ -- Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and...

Dr. Thao Nguyen Joins DermOne in Grand Prairie

DermOne Dermatology Associates of Texas, P.A., is pleased to announce the addition of Thao Nguyen, M.D., a board-certified dermatologist with expertise in all areas of medical, su...

DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development

CUPERTINO, Calif., Sept. 20, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Myriam Theeuwes has joined DURECT as Senior Vice President, Clinical Development.  Dr....

Crescita Therapeutics™ Reports Positive Topline Results of Phase 2 Clinical Trial for the Treatment of Plaque Psoriasis

MISSISSAUGA, ON, Sept. 18, 2017 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare ...

Nuclear Receptor ROR Gamma Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC Pipeline Review, H2 2017 [Report Updated: 29082017] Prices from USD

Nuclear Receptor ROR Gamma Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC Pipeline Revi...

Global States Cytotoxic Drug Market Data Survey Report 2025 [Report Updated: 30082017] Prices from USD $1500

SummaryCytotoxic drugs inhibit or prevent the function of cells. Cytotoxic drugs are primarily used to treat cancer, frequently as part of a chemotherapy regime. Recently, their uses have expanded to ...

Janssen Research and Development, LLC: New Two-year Guselkumab Data Show Patients with Moderate to Severe Plaque Psoriasis Achieved Consistent Rates of Skin Clearance

GENEVA, Switzerland, Sept. 16, 2017  /PRNewswire/ -- More than 80 percent of patients receiving guselkumab, including patients transitioned from HUMIRA® (adalimumab) to the anti-i...

New Two-Year TREMFYA™ (guselkumab) Data Show Patients With Moderate To Severe Plaque Psoriasis Achieved Consistent Rates Of Skin Clearance

GENEVA, Sept. 16, 2017 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) presented today new longer-term data from the open-label extension of the VOYAGE 1 trial demonstrating consiste...

Janssen Receives CHMP Positive Opinion for Guselkumab Recommending Approval for the Treatment of Moderate to Severe Plaque Psoriasis in the European Union

Pending approval, guselkumab will be the first biologic that selectively blocks interleukin (IL)-23   FOR MEDICAL AND TRADE MEDIA ONLY  BEERSE, B...

Rho Associated Protein Kinase 2 Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1 Pipeline Review, H2 2017 [Report Updated: 29082017] Prices from USD $3500

Rho Associated Protein Kinase 2 Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1 Pipeline Review, H2 2017SummaryRho Associated Protein Kin...

Events [0 Results]

None

Companies [22 Associated Companies listed on BioPortfolio]

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion d...

Arrien Pharmaceuticals

Arrien Pharmaceuticals is a targeted therapeutics drug discovery and development company. Arrien applies its proprietary fragment-based FIELDS drug discovery technology to targ...

Tiziana Life Sciences plc

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The C...

Santalis Pharmaceuticals, Inc.

Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and a...

Ziarco Pharma Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, ...

Akaal Pharma Pty Ltd.

Akaal Pharma Pty Ltd (Akaal Pharma) is a clinical-stage drug discovery and development company focused on the development of novel small molecule drugs for the treatment of inflam...

Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and p...

Helmedix Pty Ltd

Helmedix is developing new therapies for autoimmune diseases. The company has identified peptides derived from helminthic worms that have immune-modulating properties. These peptides are being explo...

HealOr

Founded in 2002, HealOr is a privately owned, clinical-stage specialty biopharmaceutical company developing a first-in-class pipeline of topical therapeutics to treat a variety of...

Clinical Trials [554 Associated Clinical Trials listed on BioPortfolio]

Post-Marketing Surveillance Study of OTEZLA

To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis ...

This Study Has 2 Parts. The First Part Tests How Healthy Men Tolerate Different Doses of BI 730357 and How the Metabolism of Midazolam is Affected by BI 730357. The Second Part is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI

Part 1 of this trial is a Phase Ib evaluation of the safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) properties of Multiple Rising Dose (MRD) administration of BI 73...

Efficacy and Safety of Xenogenic AD-MSCs With Moderate to Severe Psoriasis

The purpose of this study is to evaluate the efficacy and safety of Adipose Derived Mesenchymal Stem Cells (AD-MSCs) with moderate to severe psoriasis. Any adverse events related to AD-MSC...

Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic Nail Disease

Nail psoriasis has a high incidence amongst patients with psoriasis.It is estimated to affect 80% of psoriatic patients at some time during their lives and has a significant adverse influe...

Study to Assess the Long-Term Safety of Brodalumab Compared With Other Therapies in the Treatment of Adults With Moderate-to-Severe Psoriasis

Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

A Study Examining the Medication Apremilast as Treatment for Chronic Itch

Chronic Itch is a debilitating condition affecting many people. Currently, there are no FDA-approved treatments. Apremilast is an FDA-approved oral medication used to successfully treat th...

A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China

The objective of this non-interventional, observational study is to assess the effectiveness and patient reported outcome of adalimumab in patients with moderate to severe psoriasis in rea...

Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.

This trial will investigate the safety, tolerability and pharmacokinetic (PK) data of LEO 32731 (and major human metabolite LEO 40815) in healthy male Japanese subjects. The primary object...

This is a Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis.

This is a study to assess the long-term safety, tolerability, and efficacy of bimekizumab.

PubMed Articles [326 Associated PubMed Articles listed on BioPortfolio]

Effect of topical application of black seed oil on imiquimod-induced psoriasis-like lesions in the thin skin of adult male albino rats.

Psoriasis is a chronic inflammatory skin disease that affects about 1-3% of the world's population. Black seed oil, i.e the oil extracted from black seeds (Nigella sativa seeds), possesses a broad spe...

Pro-oxidant status and Nrf2 levels in psoriasis vulgaris skin tissues and dimethyl fumarate-treated HaCaT cells.

Reactive oxygen species (ROS) contribute to pathogenesis of many inflammatory skin diseases, including psoriasis. The aim of this study is to compare antioxidant protein expression in psoriasis vulgar...

Curcumin attenuates the scurfy-induced immune disorder, a model of IPEX syndrome, with inhibiting Th1/Th2/Th17 responses in mice.

Immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX) is a lethal autoimmune disease caused by mutations in the Foxp3 gene scurfin (scurfy). Immunosuppressive therapy for IPEX pa...

Alcohol-Related Mortality in Patients With Psoriasis: A Population-Based Cohort Study.

People diagnosed with psoriasis have an increased risk of premature mortality, but the underlying reasons for this mortality gap are unclear.

Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies.

Depression is a common comorbidity in psoriasis, and both conditions are associated with systemic inflammation. The efficacy of ixekizumab, a high-affinity monoclonal antibody that selectively targets...

Developing a protocol to identify and prioritise research questions for psoriasis: A James Lind Alliance Priority Setting Partnership.

Psoriasis affects over two million people in the UK. It confers a significant psychological and social impact on individuals and an associated high economic cost to the National Health Service. There ...

Distinct Patterns and Aetiology of Chromonychia.

Abnormal colouring of the nails may be a sign of underlying systemic or local disorders. This study investigated the prevalence and causes of chromonychia as a whole, as well as of each subtype. Among...

Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.

Use of systemic therapies for moderate to severe psoriasis in children is increasing, but comparative data on their use and toxicities are limited.

Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.

Biologics have greatly improved psoriasis management. However, primary and secondary non-response to treatment requires innovative strategies to optimize outcomes.

Revisiting murine models for atopic dermatitis and psoriasis with multipolar cytokine axes.

Atopic dermatitis (AD) and psoriasis are one of the common skin diseases. Animal models are a powerful tool to analyze these diseases, which are complicated by multiple cytokine pathways. However, man...

Videos

None available.

Medical and Biotech [MESH] Definitions

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.

A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.

An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.

A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.

Quick Search
Advertisement
 

Relevant Topics

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...

review and buy Moderate-to-Severe Plaque Psoriasis market research data and corporate reports here

Channels Quicklinks